🩸 Warfarin is an anticoagulant that requires monitoring using prothrombin time (PT) and international normalized ratio (INR) to evaluate clotting status and determine whether excessive anticoagulation is contributing to bleeding.

🩸 This client presents with persistent epistaxis (nosebleed) for 4 hours despite pressure, which raises concern for an elevated INR and increased bleeding risk.

🩸 The priority nursing action is to obtain laboratory data to assess the severity of anticoagulation and guide treatment decisions.

🩸 Depending on the INR result and severity of bleeding, the provider may adjust warfarin therapy or prescribe reversal treatment.

🩸 Monitoring for additional bleeding signs such as bruising, hematuria, melena, hypotension, or tachycardia is also important.

❌ Apply a warm compress to the nose

❌ Warm compresses promote vasodilation, which may worsen bleeding rather than control it.

❌ Nosebleeds are generally managed initially with pressure and sometimes cold application—not heat.

❌ Administer intravenous alteplase

❌ Alteplase is a thrombolytic medication that dissolves clots and would significantly increase bleeding risk.

❌ It is contraindicated in a patient already experiencing active bleeding.

❌ Administer protamine sulfate

❌ Protamine sulfate is the reversal agent for heparin, not warfarin.

❌ Warfarin reversal typically involves vitamin K (phytonadione) and other measures depending on severity.

🧠 Montelukast is a leukotriene receptor antagonist commonly prescribed for asthma maintenance and allergic rhinitis.

🧠 An important adverse effect requiring immediate reporting is neuropsychiatric changes, including depression, mood changes, agitation, anxiety, sleep disturbances, suicidal thoughts, and behavioral changes.

🧠 Clients and families should be educated to monitor for emotional or behavioral changes after starting therapy.

🧠 Because these reactions can be serious, the client should contact the healthcare provider promptly if symptoms occur.

🧠 Montelukast is used for prevention and maintenance and should not be used to treat an acute asthma attack.

❌ Blurred vision

❌ Blurred vision is not a common or priority adverse effect associated with montelukast.

❌ Although vision changes should be evaluated if severe, they are not the primary teaching point.

❌ Palpitations

❌ Palpitations are not typically associated with montelukast therapy.

❌ Cardiovascular monitoring is not the main concern for this medication.

❌ Constipation

❌ Constipation is not a major adverse effect commonly emphasized during montelukast education.

❌ Neuropsychiatric symptoms are more clinically significant.

❤️ Hydralazine is a direct vasodilator that lowers blood pressure by relaxing vascular smooth muscle and reducing peripheral resistance.

❤️ Excessive hydralazine effects or toxicity can lead to reflex tachycardia, where the heart rate increases in response to vasodilation and falling blood pressure.

❤️ Clients may also experience palpitations, hypotension, flushing, headache, dizziness, and chest discomfort.

❤️ Tachycardia occurs because the body attempts to maintain adequate cardiac output after blood vessels dilate.

❤️ Nurses should monitor heart rate, blood pressure, and symptoms of cardiovascular instability during therapy.

❌ Constipation

❌ Constipation is not a typical finding associated with hydralazine toxicity.

❌ Hydralazine primarily affects the cardiovascular system rather than gastrointestinal motility.

❌ Hypertension

❌ Hydralazine lowers blood pressure, so toxicity is more associated with hypotension, not hypertension.

❌ Elevated blood pressure would suggest inadequate treatment rather than toxicity.

❌ Seizure

❌ Seizures are not a classic clinical finding of hydralazine toxicity.

❌ Cardiovascular effects such as reflex tachycardia are more expected.

🫀 Amlodipine is a calcium channel blocker (CCB) used to treat hypertension and angina by relaxing blood vessels and reducing peripheral vascular resistance.

🫀 One of the most common adverse effects is peripheral edema, especially swelling of the feet, ankles, and lower legs.

🫀 This occurs because vasodilation increases pressure within peripheral capillaries, causing fluid to move into surrounding tissues.

🫀 The nurse should monitor for ankle swelling, weight gain, tight shoes, and lower-extremity enlargement during therapy.

🫀 Clients should also be monitored for hypotension, dizziness, flushing, and headache.

❌ Respiratory infection

❌ Respiratory infection is not a typical adverse effect associated with amlodipine.

❌ Amlodipine primarily affects the cardiovascular system rather than increasing infection risk.

❌ Watery diarrhea

❌ Diarrhea is not a common or priority adverse reaction of amlodipine.

❌ Gastrointestinal symptoms are less characteristic than vascular effects.

❌ Hypertension

❌ Amlodipine is prescribed to lower blood pressure, not cause hypertension.

❌ The nurse is more concerned about hypotension than elevated blood pressure.

🟡 Fenofibrate is a fibric acid derivative used to lower triglycerides and cholesterol levels.

🟡 An important adverse reaction to monitor for is hepatotoxicity, which may present as jaundice (yellowing of the skin or eyes).

🟡 Jaundice can indicate liver dysfunction or impaired bile processing, requiring prompt evaluation by the healthcare provider.

🟡 Clients taking fenofibrate may require periodic monitoring of liver function tests (AST, ALT, bilirubin) during therapy.

🟡 The nurse should also monitor for symptoms such as dark urine, abdominal pain, fatigue, and unusual weakness.

❌ Blurry vision

❌ Blurry vision is not a common or hallmark adverse reaction associated with fenofibrate.

❌ Visual changes should still be evaluated but are not the priority concern.

❌ Hyperglycemia

❌ Fenofibrate is not primarily associated with causing elevated blood glucose levels.

❌ Monitoring focuses more on liver and muscle effects.

❌ Increased potassium

❌ Hyperkalemia is not a typical adverse effect of fenofibrate therapy.

❌ Electrolyte changes are not the major monitoring concern for this medication.